Generic Medicine Info
Indications and Dosage
Induction of anaesthesia
Adult: 1-2 mg (15-30 mcg/kg) via slow inj.

Short-term management of insomnia
Adult: 0.5-1 mg at night. Max: 2 mg daily.
Elderly: Initial dose: 0.5 mg at night; up to 1 mg, if necessary.

Premedication in surgery
Adult: 1-2 mg (15-30 mcg/kg) as a single dose. May also be given via IM inj.
May be taken with or without food.
Preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; chronic psychosis, phobic or obsessional states; may precipitate suicide or aggressive behavior; not to be used alone to treat depression or anxiety associated with depression; glaucoma. Pregnancy, lactation. Neonates.
Special Precautions
Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; personality disorders or organic brain changes; history of alcohol or drug addiction. resp depression and hypotension with parenteral admin; this route should only be used when facilities for reversing resp depression are available.
Adverse Reactions
Drowsiness and lightheadedness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia.
Drug Interactions
Enhanced sedation or resp and CV depression with drugs with CNS depressant properties eg, antidepressants, antihistamines, antipsychotics, general anaesthetics, other hypnotics or sedatives, opioid analgesics and cisapride. Alcohol. Calcium-channel blockers; clonidine; diaxozide; disulfiram; clozapine; diuretics; moxonidine; nabitone; nitrates; cimetidine, esomeprazole and omeprazole; muscle relaxants; dopaminergics; lofexidine; hydralazine, minoxidil and nitroprusside; antifungals; angiotensin II receptor antagonist; antiepileptics; β-blockers; antibacterials.
Potentially Fatal: Drugs which alter the hepatic microsomal enzymes.
Mechanism of Action: Flunitrazepam is a short-acting benzodiazepine with general properties similar to diazepam.
Absorption: Readily absorbed from the GI tract.
Distribution: About 77-80% is bound to plasma proteins.
Metabolism: Extensively metabolised hepatically.
Excretion: Mainly in the urine as metabolites. Elimination half-life: 16-35 hr.
MIMS Class
Hypnotics & Sedatives
Disclaimer: This information is independently developed by MIMS based on Flunitrazepam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in